Fair Value Calculator Fair Value Calculator
EN DE

1518 (1518) Fair Value & Analysis

Healthcare · Market cap HK$205M

1 1518 1518 · HK
PriceHK$0.4000
Fair ValueHK$0.3900
Upside-2.5%
Quality41/100
Watch 1518 for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range HK$0.3100 – HK$0.4600

Fair value as of: Jul 2, 2026

From 9 valuation models · updated today

Share price −20.6% over the past month.

Price vs Fair Value (12 months)

HK$0.8889 HK$0.3951 Fair Value HK$0.3900 Jun 2025 Jul 2026

12‑month range HK$0.3951 – HK$0.8889 · fair‑value band HK$0.3100 – HK$0.4600 · the HK$0.4000 price screens above the HK$0.3900 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1518 (1518) currently trades at HK$0.4000, while our model-based Fair Value estimate is HK$0.3900 — implying the stock looks roughly 2.5% overvalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 1518 generated revenue of HK$600M at a net margin of -19.2%. Revenue declined 31.3% year over year. It earns a return on equity of -23.0%. The balance sheet holds a net cash position of HK$64.0M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$600M
Revenue growth (YoY) -31.3%
Net margin -19.2%
Return on equity -23.0%
Free cash flow HK$8.3M FY2025
Operating margin -3.7%
More key figures
EPS (TTM) HK$-0.1400
EPS growth (YoY) -63.7%
Net cash HK$64.0M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1518 reported revenue of HK$600M in FY2025 versus HK$633M in FY2021, a compound −1.3%/yr. Reported net income was −HK$115M in FY2025.

Revenue −1.3%/yr
FY21 HK$633M
FY22 HK$636M
FY23 HK$933M
FY24 HK$846M
FY25 HK$600M
Net income
FY21 −HK$101M
FY22 −HK$298M
FY23 HK$84.2M
FY24 HK$47.4M
FY25 −HK$115M

Is 1518 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc H1CA34 R$95.75 R$123.65 +29%
Fresenius SE FSNUY $11.47 $8.55 -25%
5225 5225 8.71 MYR 4.87 MYR -44%
IHHHF IHHHF $1.71 $1.17 -32%
Tenet Healthcare Corporation THC $164.77 $280.85 +70%
Rede D'Or São Luiz S.A RDOR3 R$32.50 R$46.04 +42%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 1518 (1518) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.3900 versus a price of HK$0.4000 — about −3% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 1518?
Our model-based fair value for 1518 is HK$0.3900 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.4000.
What is the quality score of 1518?
1518 has a Quality Score of 41/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 1518 (1518)?
1518 reported trailing-twelve-month revenue of about HK$600M (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 1518?
The net profit margin of 1518 is about -19.2%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.